InventisBio Co.

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, InventisBio Co. sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 2 currently recruiting 7 completed early-phase tilt top decile by trial count

InventisBio Co.: 11 sponsored US clinical trials, 2 recruiting.

InventisBio Co. sponsors 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gout, with 1 trials.

Top-decile sponsor footprint

InventisBio Co. ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 2

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

NCT07489885
RECRUITING Phase 1

Healthy Volunteer Study

NCT07270783
ACTIVE NOT RECRUITING Phase 2

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout

NCT05665699
ACTIVE NOT RECRUITING Phase 1

Study to Evaluate D-1553 in Subjects With Solid Tumors

NCT04585035
COMPLETED Phase 1

Study in Healthy Adult Female Subjects

NCT05339633
COMPLETED Early Phase 1

Evaluation of PK and Safety of D-0120 and Allopurinol

NCT05360628
COMPLETED Phase 1

Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects

NCT05226338
COMPLETED Phase 1

Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers

NCT04097405
COMPLETED Phase 1

Food Effect Study of D-0502 Tablet in Healthy Volunteers

NCT03810625
COMPLETED Phase 1

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

NCT03471663
COMPLETED Phase 1

D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers

NCT03291782

Phase Distribution

PhaseTrial count
Phase 1 9
Phase 2 2

Therapeutic Areas

Gout 1
CRC 1
NSCLC 1
Solid Tumor, Adult 1
Breast Cancer 1
Healthy Volunteer 1

What is open in the InventisBio Co. pipeline

2 recruiting of 11 indexed (18% open); 7 completed (64%).

Phase mix: 0 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Gout (1 trial), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

InventisBio Co.: open-pipeline peers nationwide

Peers matched on 11 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

InventisBio Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10152025 0%5%10%15%20% Total trials Recruiting share InventisBio Co.Aderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeBurke Medical Research InstituteGrand Valley State UniversityImunonKansas State University
InventisBio Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

InventisBio Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this InventisBio Co. page

11 registered trials is a research-attention snapshot, not an endorsement of InventisBio Co. or any single study.

  • 2 of InventisBio Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Gout is the condition InventisBio Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gout trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. InventisBio Co. pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.